Thanks to modern imaging and molecular characterization, neuroendocrine tumours can now be detected and classified in a much more targeted manner. New therapeutic procedures such as radioligand therapy and targeted drugs are increasingly enabling individualized treatment strategies.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- ENETS
- ENETS-certified center Inselspital Bern
- gastroenteropancreatic NET peptide receptor radionuclide therapy (PRRT)
- heterogeneous group of neoplasms
- Hormone-producing cells of the neuroendocrine system
- NET histopathological and immunohistochemical examinations
- NET localizations of the gynaecological tract
- NET precise morphological and molecular characterization
- NET somatostatin receptor expression
- NET Somatostatin receptor PET/CT
- NET Tumor Biology
- NET University Hospital Zurich
- Neuroendocrine tumors (NET)
- SeqEveRIV study
- SwissNET
You May Also Like
- CRC, AML and melanoma in focus
Molecular mechanisms of tumor plasticity
- Friedreich's ataxia
Interim analyses of the PROFA study show “Unmet needs”
- Study report
Sphingolipid profile in early-stage primary biliary cholangitis
- Angiosarcoma of the heart
A diagnostic and therapeutic “black box”
- Ataxias
Friedreich’s ataxia: when the energy metabolism attacks the nervous system
- Risk of osteoporosis in autoimmune liver diseases
Always determine bone density in PBC, PSC and AIH
- Neuroendocrine tumors
Precision medicine in diagnostics and therapy
- Case report: Complication after type 2 diabetes